KBC

Technical Summary

Indicator	Value	Trend

Indicator	Value	Trend

Indicator	Value	Trend

Indicator	S3	S2	S1	P	R1	R2	R3

News

Reuters - 4 days ago

FX steady after ECB rate cut

CEE MARKETS-FX steady after ECB rate cut By Alan Charlish WARSAW, Sept 13 (Reuters) - Central European currencies hovered near recent levels on Friday, as markets pared back bets on further easing from the European Central Bank and weighed inflation data from Poland. The ECB cut interest rates again on Thursday and signalled a "declining path" for borrowing costs in the months ahead.

Reuters - 5 days ago

CZECH CENTRAL BANK: LEAVES COUNTERCYCLICAL CAPITAL BUFFER RATE FOR BANKS AT 1.25%

Czech central bank leaves countercyclical buffer rate unchanged PRAGUE, Sept 12 (Reuters) - The Czech National Bank (CNB) said on Thursday the board decided to leave the countercyclical capital buffer rate applied to banks steady at 1.25% after two previous cuts this year. "This was prompted above all by an assessment of cyclical risks, which remain stable even as the Czech economy gradually shifts to the start of the expansionary phase of the financial cycle," the CNB said in a statement after

Reuters - 3 weeks ago

Ackermans & van Haaren up as private banking drives strong H1 performance

BUZZ-Ackermans & van Haaren up as private banking drives strong H1 performance ** Shares in Ackermans & van Haaren ACKB.BR are up 3.2% after the Belgium-listed holding firm posted strong H1 results carried largely by private banking ** KBC Securities highlights the net result before capital gains/losses rose by 38% to 224.2 mln euros ($248.4 mln) "

Reuters - 3 weeks ago

Currencies steady as Hungary central bank set to pause after 15 rate cuts

CEE MARKETS-Currencies steady as Hungary central bank set to pause after 15 rate cuts By Boldizsar Gyori BUDAPEST, Aug 27 (Reuters) - Central European currencies were little changed on Tuesday ahead of a Hungarian central bank rate decision likely delivering the first pause in its policy easing after more than a year. Hungary's central bank is expected to pause its easing cycle on Tuesday after 15 consecutive rate cuts beginning in May 2023, cautioned by Hungarian headline inflation HUCPIY=ECI r

Reuters - 4 weeks ago

Galapagos rises on FDA clearance for phase 1/2 1 study

BUZZ-Galapagos rises on FDA clearance for phase 1/2 ATALANTA-1 study ** Shares in Galapagos GLPG.AS rise 2.7%, paring earlier gains of as much as 4%, after the Belgian biotech company obtained FDA clearance to initiate its ATALANTA-1 study with GLPG5101 in the U.S. ** "We see the FDA clearance as an important milestone for Galapagos' GLPG5101 program," says KBC Securities, adding the company will now be able to start treating patients in the U.S.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

KBC